PRODUCT INFORMATION ANAMORPH
|
|
- Jordan Greene
- 6 years ago
- Views:
Transcription
1 PRODUCT INFORMATION ANAMORPH NAME OF DRUG ANAMORPH Tablets contain morphine sulfate 30 mg. DESCRIPTION Morphine is a phenanthrene-derivative opiate agonist. Morphine is the chief opium alkaloid which is dried or partially dried latex from the capsules of Papaver sonniferum. Morphine sulfate has the following structural formula (CAS ): HO O H HO H H NMe.H 2 SO 4.5H 2 O 2 Morphine sulfate is chemically known as 7,8-didehydro-4,5-epoxy-17-methylmorphinan- 3,6-diol sulfate (2:1) (salt) pentahydrate. Morphine sulfate has a molecular formula of (C 17 H 19 NO 3 ) 2, H 2 SO 4, 5H 2 O and a molecular weight of Morphine sulfate is an odourless, white or almost white, acicular crystals, cubical masses, or crystalline powder. When exposed to air it gradually loses water of hydration. It darkens on prolonged exposure to light. Solubility: Morphine sulfate is very soluble in water, and is very slightly soluble in alcohol. It is practically insoluble in toluene, and insoluble in chloroform and in ether. Excipients: Anamorph tablets contain the following excipients: lactose, carmellose sodium and magnesium stearate. ANAMORPH- Product Information Page 1 of 8
2 PHARMACOLOGY Actions Morphine is an opioid analgesic, which binds with stereospecific receptors at many sites within the central nervous system (CNS) to alter processes affecting both the perceptions of pain and the emotional response to pain. There are multiple subtypes of opioid receptors, each mediating various therapeutic and/or side effects of morphine. Morphine exerts its agonist activity primarily at the mu () opioid receptors. In addition to analgesia, alterations in mood including euphoria and dysphoria, drowsiness and mental clouding commonly occur. Cough suppression is mediated through direct effect on the medullary centre. Respiratory depression results from reduced responsiveness of the respiratory centre to carbon dioxide. Even at therapeutic doses, all phases of respiratory activity (rate, minute volume and tidal exchange) are depressed. Nausea and emesis are a consequence of direct stimulation of the chemoreceptor trigger zone. Biliary tract pressure may result from morphine induced spasm of the Sphincter of Oddi. Constipation is secondary to the narcotic action on bowel wall nerve plexuses. Pharmacokinetics Absorption: Morphine salts are well absorbed from the gastrointestinal tract but have poor oral bioavailability since they undergo extensive first pass metabolism in the liver and gut. The majority of a dose of morphine is conjugated with glucuronic acid in the liver, and the gut to produce morphine-3-glucuronide and morphine-6-glucuronide. The latter is considered to contribute to the analgesic effects of morphine, especially when repeated doses are given by mouth. Other active metabolites include normorphine, codeine, and morphine ethereal sulfate. Distribution: Morphine is distributed throughout the body, but mainly in the kidneys, lungs, liver and spleen, with lower concentrations in the brain and muscles. Morphine crosses the blood brain barrier less readily than more lipid-soluble opioids such as diamorphine, but it has been detected in the CSF, as have its highly polar metabolites. Excretion: About 90% of the total morphine is excreted in the urine as morphine or its metabolites within the first 24 hours of administration. Up to 10% of a dose of morphine may eventually be excreted, as conjugates through the bile into the faeces. The reminder is excreted in the urine, mainly as conjugates. Mean plasma elimination half-lives of 1.7 hours for morphine. INDICATIONS Relief of severe pain (medical and surgical) where non-narcotic analgesics and other measures do not provide satisfactory relief. Except in patients with terminal conditions, use of Anamorph should be restricted to short-term administration. CONTRAINDICATIONS Morphine is contraindicated in the following conditions: ANAMORPH- Product Information Page 2 of 8
3 Hypersensitivity to morphine or any of the ingredients in Anamorph tablets (see Description) Respiratory depression, or where respiratory reserve is depleted (e.g. severe emphysema, severe chronic bronchitis, kyphoscoliosis) Raised intracranial pressure or cerebrospinal pressure Acute bronchial asthma Patients with head injury or brain tumor Cardiac arrhythmias Severe CNS depression Heart failure secondary to chronic pulmonary disease Acute alcoholism or delirium tremens Severe liver or renal disease Incipient hepatic encephalopathy After operations on the biliary tract In the presence of gastrointestinal obstruction Convulsive states such as status epilepticus, tetanus and strychnine poisoning due to the stimulatory effects of morphine in the spinal cord Obstructive bowel disorders. Morphine should not be given to patients taking monoamine oxidase inhibitors or within 14 days of stopping such treatment. PRECAUTIONS Impaired Respiration: Respiratory depression is the chief hazard of all morphine preparations. Respiratory depression occurs most frequently in elderly and debilitated patients, and in those suffering from conditions accompanied by hypoxia or hypercapnia when even moderate therapeutic doses may significantly decrease pulmonary ventilation. Morphine should be used with extreme caution in patients with chronic pulmonary disease or cor pulmonale, patients having a substantially decreased respiratory reserve, and patients with pre-existing respiratory depression, hypoxia or hypercapnia. In such patients, even the usual therapeutic doses of morphine may decrease respiratory drive while simultaneously increasing airways resistance to the point of apnoea. Head Injury and Increased Intracranial Pressure: The respiratory depressant effects of morphine and its capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, morphine produces adverse reactions that may obscure the clinical course of patients with head injuries. In such patients, morphine must be used only if its use is deemed essential and then with extreme caution. Hypotensive Effect: Morphine sulfate may cause severe hypotension in the postoperative patient or any individual whose ability to maintain blood pressure has been compromised by a depleted blood volume or the administration of drugs such as phenothiazines or certain anaesthetics (see Interactions with Other Drugs). Morphine sulfate may produce orthostatic hypotension in ambulatory patients. Morphine sulfate, like all opioid analgesics, should be administered with caution to patients in circulatory shock, since vasodilation produced by the drug may further reduce cardiac output and blood pressure. ANAMORPH- Product Information Page 3 of 8
4 Supraventricular Tachycardias: Because of possible vagolytic action that may produce a significant increase in the ventricular response rate, morphine should be used with caution in patients with atrial flutter and other supraventricular tachycardias. Convulsions: Morphine may exacerbate pre-existing convulsions in patients with convulsive disorders. If dosage is escalated substantially above recommended levels because of tolerance development, convulsions may occur in individuals without a history of convulsive disorders. Hepatic or Renal Disease: Morphine may have a prolonged duration and cumulative effect in patients with kidney or liver dysfunction, with the potential for an increase of adverse effects. Biliary Surgery or Pancreatitis: Morphine may cause spasm of the biliary tract and sphincter of Oddi and should be used only when necessary, and with caution, in patients with biliary colic, operations on the biliary tract and acute pancreatitis. Acute Abdominal Condition: Morphine may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Other Special Risk Patients: Reduced doses and caution is required when prescribing morphine for certain patients such as the elderly or debilitated, those with hypothyroidism, ulcerative colitis, adrenocortical insufficiency (e.g. Addison s disease), and prostatic hypertrophy. Carcinogenicity, Mutagenicity, Impairment of Fertility: Adequate studies in animals have not been conducted to determine whether morphine sulfate has the potential for carcinogenesis or mutagenesis. Adequate studies in animals have not been performed to determine whether morphine sulfate has potential to impair fertility. Use in Pregnancy: (Category C) Opioid analgesics may cause respiratory depression in the newborn infant. Withdrawal symptoms in newborn infants have been reported with prolonged use of this class of drugs. Pregnant women should only be given Anamorph when the benefits clearly outweigh the potential risks to the fetus. The Australian categorisation definition of: Category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be further consulted for further details. Use in Lactation: Morphine is excreted in breast milk, therefore is not recommended for nursing mothers. Use in Children: Caution is advised in the administration of morphine to children up to two years of age, who may be more sensitive to the effects, especially the respiratory depressant effects. Paradoxical excitation is likely to occur in children receiving morphine. ANAMORPH- Product Information Page 4 of 8
5 Use in the Elderly: Care should be taken when prescribing for the elderly and debilitated patients. Morphine can show atypical effects. Driving and Operating Machinery: Morphine may impair the mental and/or physical ability required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Patients must be cautioned accordingly. Drug Dependence: Repeated administration may lead to physical and/or psychological dependence. Tolerance may also develop following repeated administration. Dependence, however, is not of paramount importance in the management of terminally ill patients or any patients in severe pain. Abrupt cessation, a sudden reduction in dose after prolonged use, or administration of a narcotic antagonist may result in withdrawal symptoms. If withdrawal is necessary, it must be undertaken gradually. INTERACTION WITH OTHER DRUGS Atropine: May counteract morphine-induced miosis. Cimetidine: A potentially lethal interaction causing apnoea, reduced respiratory rate and grand mal seizure has been reported. Naloxone increased respiratory rate, however confusion, disorientation, generalised twitching and periods of apnoea persisted for 80 hours. CNS depressant medications (including other opioids, sedatives or hypnotics, barbiturates, general anaesthetics, phenothiazines, tricyclic antidepressants, tranquillisers and alcohol): When combined with morphine, the additive depressant effects may produce respiratory depression, hypotension and profound sedation or coma. When such therapy is contemplated, the dose of one or both agents should be reduced. Dexamphetamine: Enhances the analgesic effects of morphine, decreases sedation and lack of alertness. Diazepam: Exacerbates hypotension produced by high dose of morphine as well as enhancing CNS depressant effects of morphine. Doxapram: Antagonises morphine-induced respiratory depression. Monoamine Oxidase Inhibitors (MAOIs): Because severe and sometimes fatal reactions have occurred in patients concurrently administered MAOIs and pethidine, morphine should not be given to patients taking non-selective MAOIs or within 14 days of stopping such treatment. It is unknown whether there is an interaction between the new selective MAOIs (e.g. moclobemide, selegiline) and morphine, therefore caution is advised with this combination (see Contraindications). Paracetamol: Morphine delays gastric emptying and will delay the absorption of paracetamol. Pentazocine, Buprenorphine (mixed agonist/antagonist opioid analgesics): May inhibit the effects of morphine or may precipitate withdrawal symptoms. Propanolol: Causes a potentially lethal increase in CNS toxicity. Thiopentone: Inactivates morphine in solution. ANAMORPH- Product Information Page 5 of 8
6 Tubocurarine and other muscle relaxants: Morphine augments the neuromuscular blockade. ADVERSE REACTIONS The major hazards associated with morphine, as with other opioid analgesics, are respiratory depression and to a lesser degree, circulatory depression. Respiratory arrest, shock and cardiac arrest have occurred. Other adverse effects include: Cardiovascular: Bradycardia, palpitations, hypotension (usually with larger doses), circulatory failure (usually at high doses), faintness, syncope, tachycardia, hypertension, facial flushing, chills. Respiratory: Respiratory depression (usually with large doses). Neurological: Confusion, vertigo, sedation, restlessness, mood changes, deepening coma (usually with high doses), increased intracranial pressure, headache, drowsiness, weakness, euphoria, dysphoria, seizures, dizziness, nervousness, agitation, hallucinations, delirium, insomnia, mental clouding or depression, physical dependence (with repeated administration) and tolerance development (with repeated administration). Dermatological and Hypersensitivity Reactions: Urticaria, pruritis, and other skin rashes including contact dermatitis. Gastrointestinal: Nausea, vomiting, constipation, anorexia, and dry mouth. Genitourinary: Urinary retention or hesitancy, ureteric spasm, oliguria, reduced libido or potency. Hepatobiliary: Biliary spasm. Endocrine: Anti-diuretic effect. Ophthalmic: Miosis. Other: Sweating, muscle rigidity, orthostatic hypotension and hypothermia. Withdrawal (Abstinence) Syndrome Physical dependence, with or without psychological dependence tends to occur on chronic administration. A withdrawal may be precipitated when morphine is abruptly discontinued or opioid antagonists administered. The following symptoms may be observed: body aches, diarrhoea, gooseflesh, anorexia, nervousness or restlessness, rhinorrhoea, sneezing, tremors or shivering, stomach cramps, nausea, sleep disturbance, unusual increase in sweating and yawning, weakness, tachycardia, unexplained fever and mydriasis. ANAMORPH- Product Information Page 6 of 8
7 DOSAGE AND ADMINISTRATION Adults: Usually half to one tablet initially; may be repeated every 4 to 6 hours. In chronic pain of carcinoma doses should be individually adjusted to provide analgesia. Geriatric: Plasma half-life is prolonged in the elderly. Longer dosage intervals or lower doses may be required. OVERDOSAGE Symptoms: Acute morphine overdosage is characterised by cold, clammy skin; confusion; convulsions; severe dizziness, severe drowsiness; low blood pressure; severe nervousness or restlessness; pinpoint pupils of eyes; slow heartbeat; slow or troubled breathing; severe weakness; and unconsciousness. Severe overdosage may result in apnoea, circulatory collapse, cardiac arrest and death. Treatment: Immediate attention should be given to the re-establishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. If clinically significant respiratory or cardiovascular depression is present, naloxone (a specific antidote for opioid overdose) is given. The usual initial adult dose is 0.40 to 2.0 mg intravenously, administered at 2 to 3 minute intervals if necessary. If no response is observed after 10 mg has been administered, the diagnosis of opioid-induced toxicity should be questioned. Children may receive an initial IV dose of 0.01 mg/kg; if this dose does not produce the desired degree of response, a subsequent dose of 0.1 mg/kg may be administered. Since the duration of action of morphine may exceed that of the antidote, the patient should be carefully monitored, and doses of the antidote repeated as needed. In physically dependent patients, use of naloxone will precipitate withdrawal symptoms. Naloxone should only be used when necessary, and the dose will need to be titrated in such patients. Naloxone should not be administered in the absence of clinically significant respiratory or cardiovascular depression. Oxygen, intravenous fluids, vasopressors and other supportive measures should be used as indicated. PRESENTATION 30 mg tablets; round, white, flat bevelled edge tablets, scored on one side and marked with letter M above breakline and numeral 30 below the breakline; blister pack; 20 s. STORAGE Store below 30C in a dry place. POISON SCHEDULE Controlled Drug (S8) ANAMORPH- Product Information Page 7 of 8
8 NAME AND ADDRESS OF SPONSOR Aspen Pharma Pty Ltd Chandos Street, St. Leonards NSW 2065 Australia Approved by the Therapeutic Goods Administration on May Last revision approved by the Therapeutic Goods Administration on 7 May ANAMORPH- Product Information Page 8 of 8
PRODUCT INFORMATION ACTACODE
PRODUCT INFORMATION ACTACODE NAME OF THE MEDICINE Actacode codeine linctus contains codeine phosphate 5 mg/ml. Codeine phosphate is (5R,6S)-7,8-didehydro-4,5-epoxy-3-methoxy-N-methylmorphinan-6-ol dihydrogen
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationPRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate
NORGESIC Orphenadrine citrate and paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: CAS number: 4682-36-4 Chemical structure: Orphenadrine citrate (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine
More informationPRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets
PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets NAME OF THE MEDICINE Active Ingredients: Paracetamol and Codeine Phosphate Paracetamol: Molecular Formula: C 8 H
More informationNEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.
1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
More informationRE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act
22 January 2019 RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act Dear Healthcare Professional, This notification
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full
More informationYour Pharmacy Paracetamol Plus, capsule shaped tablets (caplets)
New Zealand Data Sheet Product Description Your Pharmacy Plus, capsule shaped tablets (caplets) 500 mg per tablet & Codeine Phosphate 10 mg per tablet Blister packs of white, capsule-shaped tablets Composition
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationDilaudid, a narcotic analgesic, is prescribed for the relief of moderate to severe pain such as that due to:
DrugFAQs Dilaudid Generic name: Hydromorphone hydrochloride Brand names: Dilaudid Why is Dilaudid prescribed? Dilaudid, a narcotic analgesic, is prescribed for the relief of moderate to severe pain such
More informationAgonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone
Opioid Definition All drugs, natural or synthetic, that bind to opiate receptors Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone Opioid agonists increase pain threshold
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME Codeine Phosphate Tablets (PSM) 15 mg, 30 mg & 60 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Codeine Phosphate Hemihydrate BP 15 mg
More informationNausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.
Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationDemerol meperidine hydrochloride
Demerol meperidine hydrochloride injection, USP Rx only DESCRIPTION Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationDBL NALOXONE HYDROCHLORIDE INJECTION USP
Name of medicine Naloxone hydrochloride Data Sheet New Zealand DBL NALXNE HYDRCHLRIDE INJECTIN USP Presentation DBL Naloxone Hydrochloride Injection USP is a sterile, clear, colourless solution, free from
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol Hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER Meptid 100 mg/ml Solution for Injection Meptazinol Hydrochloride Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More informationpatient group direction
MORPHINE SULPHATE (Oral) v01 1/8 MORPHINE SULPHATE (Oral) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic)
More informationNEW ZEALAND DATA SHEET
DHC CONTINUS 60mg tablets Dihydrocodeine hydrogen tartrate 1 PRODUCT NAME DHC CONTINUS 60mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Dihydrocodeine hydrogen tartrate 60mg Excipient(s) with known
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationPRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets
PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET VERGO 16 1. Product Name Vergo 16, 16 mg, tablet. 2. Qualitative and Quantitative Composition Each tablet contains 16 mg of betahistine dihydrochloride. For the full list of excipients,
More informationPRODUCT INFORMATION APOHEALTH PARACETAMOL PLUS CODEINE & CALMATIVE paracetamol 500mg codeine phosphate 10mg and doxylamine succinate 5.
Product Information Page 1 PRODUCT INFORMATION APOHEALTH PARACETAMOL PLUS CODEINE & CALMATIVE paracetamol 500mg codeine phosphate 10mg and doxylamine succinate 5.1mg tablets NAME OF THE MEDICINE Paracetamol
More informationPRODUCT INFORMATION Panadeine EXTRA
PRODUCT INFORMATION Panadeine EXTRA COMPOSITION Each caplet brand of capsule-shaped tablet contains: Paracetamol 500 mg Codeine phosphate 15 mg and Maize Starch Purified Talc Pregelatinised Maize Starch
More informationPRODUCT INFORMATION LOFENOXAL
PRODUCT INFORMATION LOFENOXAL Diphenoxylate hydrochloride 2.5 mg and Atropine sulfate 25 microgram Name of the medicines Diphenoxylate Hydrochloride: C30H32N2O2, HCl M. W. = 489.1 CAS registry no.: 3810-80-8
More informationLorazepam Tablets, USP
Lorazepam Tablets, USP DESCRIPTION: Lorazepam, an antianxiety agent, has the chemical formula, 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H -1,4-benzodiazepin-2-one: Cl H N N O Cl OH It is a white
More informationPRESCRIBING ALERT
www.empr.com PRESCRIBING ALERT Dear Healthcare Professional, At MPR we strive to bring you important drug information in a concise and timely fashion. In keeping with this goal, we are pleased to bring
More information4.4 Special warnings and precautions for use
SUMMARY OF PRODUCT CHARACTERISTICS 4.3 Contraindications Durogesic is contraindicated in patients with known hypersensitivity to fentanyl or to the excipients present in the patch. Acute or postoperative
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME (strength pharmaceutical form) Methatabs, Tablet, 5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Methadone hydrochloride BP 5 mg Excipient(s)
More informationActive ingredients: Paracetamol Codeine phosphate. Chemical names: N-(4-Hydroxyphenyl)acetamide 4,5a-epoxy-3-methoxy-17-methyl-7,8-
Codapane Paracetamol / Codeine phosphate PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredients: Paracetamol Codeine phosphate Chemical names: N-(4-Hydroxyphenyl)acetamide 4,5a-epoxy-3-methoxy-17-methyl-7,8-
More informationPRODUCT INFORMATION. ORDINE oral solution (1 mg/ml, 2 mg/ml, 5 mg/ml and 10 mg/ml) The structural formula of morphine hydrochloride is
PRODUCT INFORMATION ORDINE oral solution (1 mg/ml, 2 mg/ml, 5 mg/ml and 10 mg/ml) NAME OF THE MEDICINE The structural formula of morphine hydrochloride is Morphine hydrochloride B.P. CAS Registry Number:
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationPanadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION
Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION DESCRIPTION Active Ingredients Paracetamol 500 mg Codeine Phosphate 8 mg Excipients Tablets - Starch - maize, talc - purified, stearic
More informationMigraleve, Migraleve Pink and Migraleve Yellow Product Information
Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also
More informationTRAPADOL INJECTION FOR I.V./I.M. USE ONLY
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationAUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
AUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 1 NAME OF THE MEDICINE Betahistine dihydrochloride. 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
More informationAnalgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I. Mr.D.Raju,M.pharm, Lecturer
Analgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I Mr.D.Raju,M.pharm, Lecturer Mechanisms of Pain and Nociception Nociception is the mechanism whereby noxious peripheral stimuli are transmitted to
More informationPRODUCT INFORMATION MERSYNDOL FORTE TABLETS
PRODUCT INFORMATION MERSYNDOL FORTE TABLETS NAME OF THE MEDICINE Non-proprietary Name Paracetamol, codeine phosphate and doxylamine succinate DESCRIPTION Each tablet contains paracetamol 450 mg, codeine
More informationPANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other.
Product description PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other. Ingredients Active Ingredients: Paracetamol
More informationAUSTRALIAN PRODUCT INFORMATION, PAINSTOP DAY-TIME PAIN RELIEVER (PARACETAMOL 120MG IN 5ML AND CODEINE PHOSPHATE HEMIHYDRATE 5MG IN 5ML)
AUSTRALIAN PRODUCT INFORMATION, PAINSTOP DAY-TIME PAIN RELIEVER (PARACETAMOL 120MG IN 5ML AND CODEINE PHOSPHATE HEMIHYDRATE 5MG IN 5ML) 1. NAME OF THE MEDICINE Paracetamol and codeine phosphate hemihydrate.
More informationPRODUCT INFORMATION. Codral* Original Cold & Flu Tablets
PRODUCT INFORMATION Codral* Original Cold & Flu Tablets Product description Codral* Original Cold & Flu tablets contain paracetamol 500 mg, pseudoephedrine hydrochloride 30 mg and codeine phosphate 6 mg.
More informationPRODUCT INFORMATION. AKINETON (biperiden hydrochloride 2 mg tablets)
PRODUCT INFORMATION AKINETON (biperiden hydrochloride 2 mg tablets) NAME OF THE MEDICINE Non-proprietary name: biperiden hydrochloride Structural formula (biperiden): Chemical name (biperiden): α-5-norbornen-2-yl-α-phenyl-1-piperidine
More informationFacts About BELBUCA (buprenorphine) Buccal Film
Facts About BELBUCA (buprenorphine) Buccal Film Indication BELBUCA is a recent FDA-approved medication for the treatment of chronic pain severe enough to require daily, around-the-clock, long-term opioid
More informationAPO-PARACETAMOL/CODEINE 500/30
APO-PARACETAMOL/CODEINE 500/30 NAME OF THE MEDICINE Paracetamol/Codeine 500/30. Chemical Name: Paracetamol: N-(4-Hydroxyphenyl) acetamide Codeine: (5R, 6S)-7, 8-didehydro-4,5-epoxy-3-methoxy-Nmethylmorphinan-6-ol
More informationPackage leaflet: Information for the user. Morfin Abcur 10 mg/ml, solution for injection. morphine hydrochloride
Package leaflet: Information for the user Morfin Abcur 10 mg/ml, solution for injection morphine hydrochloride Read all of this leaflet carefully before you start using this medicine because it contains
More informationEach tablet contains 30mg Codeine Phosphate Ph Eur. Excipient with known effect: Also contains mg of lactose.
1 NAME OF THE MEDICINAL PRODUCT Codeine Phosphate Tablets BP 30mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 30mg Codeine Phosphate Ph Eur. Excipient with known effect: Also contains
More informationBRICANYL INJECTION. terbutaline sulfate PRODUCT INFORMATION
BRICANYL INJECTION terbutaline sulfate PRODUCT INFORMATION NAME OF THE MEDICINE Terbutaline sulfate, 2-(tert-butylamino)-1-(3,5-dihydroxyphenyl) ethanol sulfate, a sympathomimetic bronchodilator with a
More informationMORPHINE Juno. (morphine hydrochloride injection) DATA SHEET
1. PRODUCT NAME MORPHINE Juno (morphine hydrochloride injection) DATA SHEET The name of the medicine is Morphine Juno as morphine hydrochloride trihydrate, (10mg /ml, 20mg /ml, 50mg /5mL, 100mg/5mL) Solution
More informationRAFEN PLUS Ibuprofen 200mg/Codeine phosphate 12.8mg tablets PRODUCT INFORMATION
RAFEN PLUS Ibuprofen 200mg/Codeine phosphate 12.8mg tablets PRODUCT INFORMATION Composition RAFEN PLUS tablet is a white to off-white capsule-shaped, biconvex tablet, containing ibuprofen 200mg and codeine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Morfin Abcur, 10 mg/ml, solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 10 mg morphine hydrochloride
More informationPANADOL SINUS DAY & NIGHT TABLETS PRODUCT INFORMATION
Product description PANADOL SINUS DAY tablet is a white, film-coated capsule-shaped tablet with flat edges, front and back faces marked with DAY. PANADOL SINUS NIGHT tablet is a white, film-coated round
More informationNARCAN Injection. 4,5 α Epoxy-3,14 dihydroxy 17 (prop-2-enyl)morphinan-6-one hydrochloride
NAME OF MEDICINE Naloxone hydrochloride The molecular weight of naloxone hydrochloride is 363.84 and the CAS registry number for the drug substance (naloxone hydrochloride) is 357-08-4. The molecular formula
More informationPRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets
PRODUCT INFORMATION Sudafed* Sinus Day + Night Relief Tablets Product description Sudafed* Sinus Day + Night Relief tablets contain two separate formulations: day tablets and night tablets. Each Sudafed*
More informationRoxane Laboratories, Inc. Columbus, Ohio MEPERIDINE HYDROCHLORIDE Tablets USP. MEPERIDINE HYDROCHLORIDE Oral Solution USP DESCRIPTION
10003964/05 Roxane Laboratories, Inc. Columbus, Ohio 43216 MEPERIDINE HYDROCHLORIDE Tablets USP MEPERIDINE HYDROCHLORIDE Oral Solution USP WARNING: May be habit forming DESCRIPTION Meperidine hydrochloride,
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. MEPHENON 10mg/1ml, solution for injection MEPHENON 5mg, tablets. Methadone hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER MEPHENON 10mg/1ml, solution for injection MEPHENON 5mg, tablets Methadone hydrochloride Read all of this leaflet carefully before you start using this medicine
More informationPRODUCT INFORMATION PANADEINE FORTE
PRODUCT INFORMATION PANADEINE FORTE NAME OF THE MEDICINE Non-proprietary Name Paracetamol and codeine phosphate DESCRIPTION Each capsule-shaped tablet contains Paracetamol 500 mg, Codeine phosphate 30
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More informationEach tablet contains 15mg Codeine Phosphate Ph Eur
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Codeine Phosphate Tablets BP 15mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 15mg Codeine Phosphate Ph Eur For the
More informationTEMGESIC Injection Buprenorphine (as hydrochloride)
TEMGESIC Injection Buprenorphine (as hydrochloride) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about TEMGESIC. It does not contain all the available
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More informationCore Safety Profile. Pharmaceutical form(s)/strength: 5mg/ml and 25 mg/ml, Solution for injection, IM/IV FI/H/PSUR/0010/002 Date of FAR:
Core Safety Profile Active substance: Esketamine Pharmaceutical form(s)/strength: 5mg/ml and 25 mg/ml, Solution for injection, IM/IV P-RMS: FI/H/PSUR/0010/002 Date of FAR: 29.05.2012 4.3 Contraindications
More informationThis leaflet answers some common questions about Momex SR Tablets.
Momex SR Modified (Sustained) Release Tablets [Morphine sulphate] CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Momex SR Tablets. It does not contain
More informationSummary of risk management plan for Dzuveo (Sufentanil (as citrate))
Part VI: Summary of the risk management plan Summary of risk management plan for Dzuveo (Sufentanil (as citrate)) This is a summary of the risk management plan (RMP) for Dzuveo. The RMP details important
More informationTUSSIGON (hydrocodone bitartrate and homatropine methylbromide) tablets, for oral administration, CII Initial U.S. Approval: 1943
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TUSSIGON safely and effectively. See full prescribing information for TUSSIGON. TUSSIGON (hydrocodone
More informationPRODUCT INFORMATION. ORDINE oral solution 1 mg/ml, 2 mg/ml, 5 mg/ml and 10 mg/ml
PRODUCT INFORMATION ORDINE oral solution 1 mg/ml, 2 mg/ml, 5 mg/ml and 10 mg/ml NAME OF THE MEDICINE Morphine hydrochloride The structural formula of morphine hydrochloride is: CAS Registry Number: 52-26-6
More information5.3 Misuse, Abuse and Diversion of Opioids 5.4 Interactions with Alcohol and other CNS Depressants 1 INDICATIONS AND USAGE
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPANA ER safely and effectively. See full prescribing information for OPANA ER. OPANA ER (oxymorphone
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Codeine Phosphate 30 mg Tablets BP 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 30mg Codeine Phosphate. For the full
More informationPackage leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate
Package leaflet: Information for the patient Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate Read all of this leaflet carefully before you start using this medicine because
More informationPATIENT INFORMATION LEAFLET TAPENCET ER 50 (TAPENTADOL EXTENDED RELEASE 50 MG, TABLETS)
PATIENT INFORMATION LEAFLET TAPENCET ER 50 (TAPENTADOL EXTENDED RELEASE 50 MG, TABLETS) Read this entire leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME DBL Pethidine Hydrochloride Injection BP 50mg/ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION DBL Pethidine Hydrochloride Injection BP is available as a 50 mg/1 ml,
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol
PACKAGE LEAFLET: INFORMATION FOR THE USER Meptid 100 mg/ml Solution for Injection Meptazinol Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need
More informationMolecular formula: Molecular weight: C 8 H 9 NO 2 CAS Registry no.:
Parapane Paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: Paracetamol N-(4-hydroxyphenyl) Structural formula: Molecular formula: 151.20 Molecular weight: C 8 H 9 NO
More informationPackage leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate)
Package leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate) Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationSeptember 5 9, 2017 The Cosmopolitan of Las Vegas Program Guide. Program guide is sponsored by
17 September 5 9, 2017 The Cosmopolitan of Las Vegas Program Guide Program guide is sponsored by TIME TO DUAL TWO SOURCES OF PAIN ONE SOURCE OF RELIEF NUCYNTA ER is the first and only FDA-approved long-acting
More informationSlide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
More informationPRODUCT INFORMATION. Benadryl* for the Family Nightime Oral Liquid
Product description PRODUCT INFORMATION Benadryl* for the Family Nightime Oral Liquid Each 5 ml of Benadryl* Nightime oral liquid contains dextromethorphan hydrobromide 10 mg and diphenhydramine hydrochloride
More informationPRODUCT INFORMATION. Sudafed* Sinus + Allergy & Pain Relief Tablets
PRODUCT INFORMATION Sudafed* Sinus + Allergy & Pain Relief Tablets Name of the Medicine Paracetamol CAS 2 Registry Number: 103-90-2 Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 Triprolidine
More informationPRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets
PRODUCT INFORMATION Sudafed* Sinus Day + Night Relief Tablets Name of the Medicine Paracetamol CAS 2 Registry Number: 103-90-2 Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 Triprolidine
More informationPRODUCT INFORMATION PRODEINE 15 H 3 CO. Paracetamol MW Codeine phosphate MW
PRODUCT INFORMATION PRODEINE 15 NAME OF THE MEDICINE Non-proprietary Name Paracetamol and codeine phosphate. Chemical Structure HO O H N CH 3 NH CH 3 H H 3 CO Paracetamol MW 151.17 Codeine phosphate MW
More informationDBL MAGNESIUM SULFATE CONCENTRATED INJECTION
DBL MAGNESIUM SULFATE CONCENTRATED INJECTION NAME OF MEDICINE Magnesium Sulfate BP DESCRIPTION DBL Magnesium Sulfate Concentrated Injection is a clear, colourless, sterile solution. Each ampoule contains
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationPRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets
PRODUCT INFORMATION Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets Product description Sudafed* Sinus + Anti-inflammatory Pain Relief caplets contain pseudoephedrine hydrochloride 30 mg and ibuprofen
More informationImmodium / loprarmide
Immodium / loprarmide IMODIUM (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease.
More informationDrugs Used In Management Of Pain. Dr. Aliah Alshanwani
Drugs Used In Management Of Pain Dr. Aliah Alshanwani 1 Drugs Used In Management Of Pain A CASE OF OVERDOSE Sigmund Freud, the father of psychoanalysis His cancer of the jaw was causing him increasingly
More information50% Concentrated Injection
NAME OF THE MEDICINE. The molecular weight of the compound is 246.5 and the CAS registry number is 10034-99-8. The molecular formula is MgSO4, 7H2O. DESCRIPTION MAGNESIUM SULFATE HEPTAHYDRATE 50% CONCENTRATED
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More informationRead all of this leaflet carefully before you start taking this medicine. If you have any further questions, ask your doctor or pharmacist.
PACKAGE LEAFLET: INFORMATION FOR THE USER Codeine Phosphate 15mg Tablets BP Codeine Phosphate 30mg Tablets BP Codeine Phosphate 60mg Tablets BP (Codeine Phosphate) Read all of this leaflet carefully before
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. (Pentazocine Lactate Injection, USP)
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION N Talwin (Pentazocine Lactate Injection, USP) Read this carefully before you start taking Talwin. This leaflet is a
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION Pr BACLOFEN Baclofen Tablets 10 mg and 20 mg This leaflet is part III of a three-part "Product Monograph" published when BACLOFEN was approved for sale in Canada and is designed
More informationCLINICAL PHARMACOLOGY
robaxin / robaxin -7 50 (methocarbamol tablets, USP) Rx Only DESCRIPT ION robaxin /robaxin -750 (methocarbamol tablets, USP), a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant
More informationDexchlorpheniramine maleate (CAS no ) is described chemically as (+)-2-[pchloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine
PRODUCT INFORMATION NAME OF THE MEDICINE POLARAMINE (dexchlorpheniramine maleate) DESCRIPTION Polaramine (dexchlorpheniramine maleate) is the dextro-isomer of chlorpheniramine maleate. It is an antihistamine
More informationNYXOID NASAL SPRAY PRODUCT INFORMATION
NYXOID NASAL SPRAY PRODUCT INFORMATION NAME OF THE MEDICINE Naloxone hydrochloride dihydrate nasal spray DESCRIPTION Naloxone hydrochloride is an off-white powder soluble in water. The chemical name is
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002-01 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More information